An endothelin antagonist for resistant hypertension

Mark Naunton

doi:10.1016/S0140-6736(10)60262-0

An endothelin antagonist for resistant hypertension

Research output: Contribution to journal › Letter › peer-review

Abstract

I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.

Original language	English
Pages (from-to)	636-636
Number of pages	1
Journal	The Lancet
Volume	375
Issue number	9715
DOIs	https://doi.org/10.1016/S0140-6736(10)60262-0
Publication status	Published - 22 Feb 2010
Externally published	Yes

Access to Document

10.1016/S0140-6736(10)60262-0

Cite this

@article{3a512e9951cd403097cd8035c99f8cf7,

title = "An endothelin antagonist for resistant hypertension",

abstract = "I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.",

author = "Mark Naunton",

year = "2010",

month = feb,

day = "22",

doi = "10.1016/S0140-6736(10)60262-0",

language = "English",

volume = "375",

pages = "636--636",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9715",

}

TY - JOUR

T1 - An endothelin antagonist for resistant hypertension

AU - Naunton, Mark

PY - 2010/2/22

Y1 - 2010/2/22

N2 - I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.

AB - I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.

UR - http://www.scopus.com/inward/record.url?scp=76749156102&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60262-0

DO - 10.1016/S0140-6736(10)60262-0

M3 - Letter

SN - 0140-6736

VL - 375

SP - 636

EP - 636

JO - The Lancet

JF - The Lancet

IS - 9715

ER -

An endothelin antagonist for resistant hypertension

Abstract

Access to Document

Other files and links

Cite this